Impact of HPV infection on the development of head and neck cancer

Brazilian Journal of Medical and Biological Research

Volumn 46, Issue 3, 2013, Pages

  Betiol, J ^a   Villa, L L ^a,b   Sichero, L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto do HPV   (Brazil)

Author keywords

Head and neck cancer; Human papillomavirus; Oncogenic potential; Viral prevalence

Indexed keywords

ALCOHOL; PROTEIN E6; PROTEIN E7; VIRUS DNA;

CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CHLAMYDIA TRACHOMATIS; DNA SYNTHESIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNITY; LARYNX CANCER; META ANALYSIS (TOPIC); MOUTH CANCER; PAPILLOMATOSIS; PAPILLOMAVIRUS INFECTION; PHARYNX CANCER; REVIEW; SEQUENCE ANALYSIS; TISSUE INJURY; TOBACCO; UNSAFE SEX; UTERINE CERVIX CANCER; VIRUS GENOME; WART VIRUS;

EID: 84876495233     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20132703     Document Type: Review

References (95)

1. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004; 68: 362-372, doi: 10.1128/MMBR.68.2.362-372.2004.
2. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324: 17-27, doi: 10.1016/j.virol.2004.03.033.
3. van Doorslaer K, Bernard HU, Chen Z, de Villiers EM, zur Hausen H, Burk RD. Papillomaviruses: evolution, Linnaean taxonomy and current nomenclature. Trends Microbiol 2011; 19: 49-50, doi: 10.1016/j.tim.2010.11.004.
4. Sichero L, Villa LL. Epidemiological and functional implications of molecular variants of human papillomavirus. Braz J Med Biol Res 2006; 39: 707-717, doi: 10.1590/S0100-879X2006000600002.
5. Burk RD, Chen Z, Harari A, Smith BC, Kocjan BJ, Maver PJ, et al. Classification and nomenclature system for human Alphapapillomavirus variants: general features, nucleotide landmarks and assignment of HPV6 and HPV11 isolates to variant lineages. Acta Dermatovenerol Alp Panonica Adriat 2011; 20: 113-123.
6. Chen Z, Schiffman M, Herrero R, Desalle R, Anastos K, Segondy M, et al. Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One 2011; 6: e20183, doi: 10.1371/journal.pone.0020183.
7. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007; 90: 1-636.
8. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4: 8, doi: 10.1186/1750-9378-4-8.
9. Villa LL, Schlegel R. Differences in transformation activity between HPV-18 and HPV-16 map to the viral LCR-E6-E7 region. Virology 1991; 181: 374-377, doi: 10.1016/0042-6822(91)90507-8.
10. O'Connor MJ, Stunkel W, Koh CH, Zimmermann H, Bernard HU. The differentiation-specific factor CDP/Cut represses transcription and replication of human papillomaviruses through a conserved silencing element. J Virol 2000; 74: 401-410, doi: 10.1128/JVI.74.1.401-410.2000.
11. Romanczuk H, Howley PM. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci U S A 1992; 89: 3159-3163, doi: 10.1073/pnas.89.7.3159.
12. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989; 8: 3905-3910.
13. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989; 8: 4099-4105.
14. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitinprotein ligase in the ubiquitination of p53. Cell 1993; 75: 495-505, doi: 10.1016/0092-8674(93)90384-3.
15. Pim D, Banks L. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. APMIS 2010; 118: 471-493, doi: 10.1111/j.1600-0463.2010.02618.x.
16. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996; 380: 79-82, doi: 10.1038/380079a0.
17. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009; 10: 321-322, doi: 10.1016/S1470-2045(09)70096-8.
18. Smith JS, Bosetti C, Munoz N, Herrero R, Bosch FX, Eluf-Neto J, et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric casecontrol study. Int J Cancer 2004; 111: 431-439, doi: 10.1002/ijc.20257.
19. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-1799, doi: 10.1086/657321.
20. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 101-105, doi: 10.1038/sj.bjc.6601024.
21. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45: 309-316, doi: 10.1016/j.oraloncology.2008.06.002.
22. Hartwig S, Syrjanen S, Dominiak-Felden G, Brotons M, Castellsague X. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 2012; 12: 30, doi: 10.1186/1471-2407-12-30.
23. American Cancer Society. Cancer facts and figures 2012. Atlanta: American Cancer Society; 2012.
24. INCA (Instituto Nacional do Câ ncer). Estimativa 2012: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2011.
25. Auluck A, Hislop G, Bajdik C, Poh C, Zhang L, Rosin M. Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population: the British Columbia experience. Cancer 2010; 116: 2635-2644.
26. Cole L, Polfus L, Peters ES. Examining the incidence of human papillomavirus-associated head and neck cancers by race and ethnicity in the US, 1995-2005. PLoS One 2012; 7: e32657, doi: 10.1371/journal.pone.0032657.
27. Castellsague X, Quintana MJ, Martinez MC, Nieto A, Sanchez MJ, Juan A, et al. The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis. Int J Cancer 2004; 108: 741-749, doi: 10.1002/ijc.11627.
28. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-3287.
29. Kruse AL, Bredell M, Gratz KW. Oral squamous cell carcinoma in non-smoking and non-drinking patients. Head Neck Oncol 2010; 2: 24, doi: 10.1186/1758-3284-2-24.
30. Dahlstrom KR, Little JA, Zafereo ME, Lung M, Wei Q, Sturgis EM. Squamous cell carcinoma of the head and neck in never smoker-never drinkers: a descriptive epidemiologic study. Head Neck 2008; 30: 75-84, doi: 10.1002/hed.20664.
31. Syrjanen K, Syrjanen S, Lamberg M, Pyrhonen S, Nuutinen J. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg 1983; 12: 418-424, doi: 10.1016/S0300-9785(83)80033-7.
32. Gillison ML, Lowy DR. A causal role for human papillomavirus in head and neck cancer. Lancet 2004; 363: 1488-1489, doi: 10.1016/S0140-6736(04)16194-1.
33. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956, doi: 10.1056/NEJMoa065497.
34. Rampias T, Boutati E, Pectasides E, Sasaki C, Kountourakis P, Weinberger P, et al. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res 2010; 8: 433-443, doi: 10.1158/1541-7786.MCR-09-0345.
35. Gillison ML, Shah KV. Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol 2001; 13: 183-188, doi: 10.1097/00001622-200105000-00009.
36. Sudhoff HH, Schwarze HP, Winder D, Steinstraesser L, Gorner M, Stanley M, et al. Evidence for a causal association for HPV in head and neck cancers. Eur Arch Otorhinolaryngol 2011; 268: 1541-1547, doi: 10.1007/ s00405-011-1714-8.
37. Marur S, D'Souza G, Westra WH, Forastiere AA. HPVassociated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11: 781-789, doi: 10.1016/ S1470-2045(10)70017-6.
38. Hemminki K, Dong C, Frisch M. Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands. Eur J Cancer Prev 2000; 9: 433-437, doi: 10.1097/00008469-200012000-00010.
39. Sinha P, Logan HL, MendenhallWM. Human papillomavirus, smoking, and head and neck cancer. Am J Otolaryngol 2012; 33: 130-136, doi: 10.1016/j.amjoto.2011.02.001.
40. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420, doi: 10.1093/jnci/djn025.
41. Termine N, Panzarella V, Falaschini S, Russo A, Matranga D, Lo Muzio L, et al. HPV in oral squamous cell carcinoma versus head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann Oncol 2008; 19: 1681-1690, doi: 10.1093/annonc/mdn372.
42. Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, Hui A, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009; 27: 6213-6221, doi: 10.1200/JCO.2009.23.1670.
43. Remmerbach TW, Brinckmann UG, Hemprich A, Chekol M, Kuhndel K, Liebert UG. PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. J Clin Virol 2004; 30: 302-308, doi: 10.1016/j.jcv.2003.12.011.
44. Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birchall MA, Thomas SJ. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 2006; 31: 259-266, doi: 10.1111/j.1749-4486.2006.01246.x.
45. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 467-475, doi: 10.1158/1055-9965.EPI-04-0551.
46. Bottalico D, Chen Z, Dunne A, Ostoloza J, McKinney S, Sun C, et al. The oral cavity contains abundant known and novel human papillomaviruses from the Betapapillomavirus and Gammapapillomavirus genera. J Infect Dis 2011; 204: 787-792, doi: 10.1093/infdis/jir383.
47. Katsenos S, Becker HD. Recurrent respiratory papillomatosis: a rare chronic disease, difficult to treat, with potential to lung cancer transformation: apropos of two cases and a brief literature review. Case Rep Oncol 2011; 4: 162-171, doi: 10.1159/000327094.
48. Shykhon M, Kuo M, Pearman K. Recurrent respiratory papillomatosis. Clin Otolaryngol Allied Sci 2002; 27: 237-243, doi: 10.1046/j.1365-2273.2002.00555.x.
49. Silver RD, Rimell FL, Adams GL, Derkay CS, Hester R. Diagnosis and management of pulmonary metastasis from recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 2003; 129: 622-629, doi: 10.1016/j.otohns.2003.08.018.
50. Gelinas JF, Manoukian J, Cote A. Lung involvement in juvenile onset recurrent respiratory papillomatosis: a systematic review of the literature. Int J Pediatr Otorhinolaryngol 2008; 72: 433-452, doi: 10.1016/j.ijporl.2007.12.003.
51. Bonnez W, Kashima HK, Leventhal B, Mounts P, Rose RC, Reichman RC, et al. Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis (RRP). Virology 1992; 188: 384-387, doi: 10.1016/0042-6822(92)90770-P.
52. Bonagura VR, Hatam LJ, Rosenthal DW, de Voti JA, Lam F, Steinberg BM, et al. Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and-11. APMIS 2010; 118: 455-470, doi: 10.1111/j.1600-0463.2010.02617.x.
53. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2008 Sub (2000-2006), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. www.seer.-cancer.gov.
54. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER cancer statistics review, 1975-2009 (Vintage 2009 Populations). Bethesda: National Cancer Institute; 2009.
55. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90, doi: 10.3322/caac.20107.
56. Bertolus C, Goudot P, Gessain A, Berthet N. Clinical relevance of systematic human papillomavirus (HPV) diagnosis in oral squamous cell carcinoma. Infect Agent Cancer 2012; 7: 13, doi: 10.1186/1750-9378-7-13.
57. Jiang R, Gu X, Moore-Medlin TN, Nathan CA, Hutt-Fletcher LM. Oral dysplasia and squamous cell carcinoma: correlation between increased expression of CD21, Epstein-Barr virus and CK19. Oral Oncol 2012; 48: 836-841, doi: 10.1016/j.oraloncology.2012.03.017.
58. Ram H, Sarkar J, Kumar H, Konwar R, Bhatt ML, Mohammad S. Oral cancer: risk factors and molecular pathogenesis. J Maxillofac Oral Surg 2011; 10: 132-137, doi: 10.1007/s12663-011-0195-z.
59. Gillison ML, Alemany L, Snijders PJ, Chaturvedi A, Steinberg BM, Schwartz S, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012; 30 (Suppl 5): F34-F54, doi: 10.1016/j.vaccine.2012.05.070.
60. Kreimer AR, Bhatia RK, Messeguer AL, Gonzalez P, Herrero R, Giuliano AR. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis 2010; 37: 386-391.
61. St Guily JL, Jacquard AC, Pretet JL, Haesebaert J, Beby-Defaux A, Clavel C, et al. Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France-The EDiTH VI study. J Clin Virol 2011; 51: 100-104, doi: 10.1016/j.jcv.2011.03.003.
62. Castillo A, Koriyama C, Higashi M, Anwar M, Bukhari MH, Carrascal E, et al. Human papillomavirus in upper digestive tract tumors from three countries. World J Gastroenterol 2011; 17: 5295-5304, doi: 10.3748/wjg.v17.i48.5295.
63. Lingen MW, Xiao W, Schmitt A, Jiang B, Pickard R, Kreinbrink P, et al. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol 2013; 49: 1-8, doi: 10.1016/j.oraloncology. 2012.07.002.
64. Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012; 307: 693-703, doi: 10.1001/jama.2012.101.
65. Kreimer AR, Villa A, Nyitray AG, Abrahamsen M, Papenfuss M, Smith D, et al. The epidemiology of oral HPV infection among a multinational sample of healthy men. Cancer Epidemiol Biomarkers Prev 2011; 20: 172-182, doi: 10.1158/1055-9965.EPI-10-0682.
66. Syrjanen S. Human papillomaviruses in head and neck carcinomas. N Engl J Med 2007; 356: 1993-1995, doi: 10.1056/NEJMe078004.
67. St Guily JL, Borget I, Vainchtock A, Remy V, Takizawa C. Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database. Head Neck Oncol 2010; 2: 22, doi: 10.1186/1758-3284-2-22.
68. Rodriguez T, Altieri A, Chatenoud L, Gallus S, Bosetti C, Negri E, et al. Risk factors for oral and pharyngeal cancer in young adults. Oral Oncol 2004; 40: 207-213, doi: 10.1016/ j.oraloncology.2003.08.014.
69. Chernock RD, El-Mofty SK, Thorstad WL, Parvin CA, Lewis JS Jr. HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol 2009; 3: 186-194, doi: 10.1007/s12105-009-0126-1.
70. El-Mofty SK, Patil S. Human papillomavirus (HPV)-related oropharyngeal nonkeratinizing squamous cell carcinoma: characterization of a distinct phenotype. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 339-345, doi: 10.1016/j.tripleo.2005.08.001.
71. Ribeiro KB, Levi JE, Pawlita M, Koifman S, Matos E, Eluf-Neto J, et al. Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol 2011; 40: 489-502, doi: 10.1093/ije/dyq249.
72. Hannisdal K, Schjolberg A, De Angelis PM, Boysen M, Clausen OP. Human papillomavirus (HPV)-positive tonsillar carcinomas are frequent and have a favourable prognosis in males in Norway. Acta Otolaryngol 2010; 130: 293-299, doi: 10.3109/00016480903071377.
73. Feller L, Wood NH, Khammissa RA, Lemmer J. Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 2: Human papillomavirus associated oral and oropharyngeal squamous cell carcinoma. Head Face Med 2010; 6: 15, doi: 10.1186/1746-160X-6-15.
74. Chu EA, Kim YJ. Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngol Clin North Am 2008; 41: 673-695, doi: 10.1016/j.otc.2008.01.016.
75. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917, doi: 10.1002/ijc.25516.
76. Duray A, Descamps G, Arafa M, Decaestecker C, Remmelink M, Sirtaine N, et al. High incidence of high-risk HPV in benign and malignant lesions of the larynx. Int J Oncol 2011; 39: 51-59.
77. Baumann JL, Cohen S, Evjen AN, Law JH, Vadivelu S, Attia A, et al. Human papillomavirus in early laryngeal carcinoma. Laryngoscope 2009; 119: 1531-1537, doi: 10.1002/ lary.20509.
78. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer Multicenter study. J Natl Cancer Inst 2003; 95: 1772-1783, doi: 10.1093/ jnci/djg107.
79. Kaminagakura E, Villa LL, Andreoli MA, Sobrinho JS, Vartanian JG, Soares FA, et al. High-risk human papillomavirus in oral squamous cell carcinoma of young patients. Int J Cancer 2012; 130: 1726-1732, doi: 10.1002/ijc.26185.
80. Miguel RE, Villa LL, Cordeiro AC, Prado JC, Sobrinho JS, Kowalski LP. Low prevalence of human papillomavirus in a geographic region with a high incidence of head and neck cancer. Am J Surg 1998; 176: 428-429, doi: 10.1016/S0002-9610(98)00246-3.
81. Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res 2010; 70: 3159-3169, doi: 10.1158/0008-5472.CAN-09-4179.
82. Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, et al. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 2007; 120: 1763-1768, doi: 10.1002/ijc.22481.
83. Gillison ML, KochWM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720, doi: 10.1093/jnci/92.9.709.
84. Boscolo-Rizzo P, Da Mosto MC, Fuson R, Frayle-Salamanca H, Trevisan R, Del Mistro A. HPV-16 E6 L83V variant in squamous cell carcinomas of the upper aerodigestive tract. J Cancer Res Clin Oncol 2009; 135: 559-566, doi: 10.1007/s00432-008-0490-3.
85. Du J, Nordfors C, Nasman A, Sobkowiak M, Romanitan M, Dalianis T, et al. Human papillomavirus (HPV) 16 E6 variants in tonsillar cancer in comparison to those in cervical cancer in Stockholm, Sweden. PLoS One 2012; 7: e36239, doi: 10.1371/journal.pone.0036239.
86. Syrjanen S. The role of human papillomavirus infection in head and neck cancers. Ann Oncol 2010; 21 (Suppl 7): vii243-vii245, doi: 10.1093/annonc/mdq454.
87. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35, doi: 10.1056/NEJMoa0912217.
88. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007; 121: 1813-1820, doi: 10.1002/ijc.22851.
89. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010; 2: 15, doi: 10.1186/1758-3284-2-15.
90. Hong AM, Martin A, Armstrong BK, Lee CS, Jones D, Chatfield MD, et al. Human papillomavirus modifies the prognostic significance of T stage and possibly N stage in tonsillar cancer. Ann Oncol 2013; 24: 215-219, doi: 10.1093/ annonc/mds205.
91. Lee LA, Huang CG, Liao CT, Lee LY, Hsueh C, Chen TC, et al. Human papillomavirus-16 infection in advanced oral cavity cancer patients is related to an increased risk of distant metastases and poor survival. PLoS One 2012; 7: e40767, doi: 10.1371/journal.pone.0040767.
92. Weinberger PM, Merkley MA, Khichi SS, Lee JR, Psyrri A, Jackson LL, et al. Human papillomavirus-active head and neck cancer and ethnic health disparities. Laryngoscope 2010; 120: 1531-1537, doi: 10.1002/lary.20984.
93. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1992-1998, doi: 10.1200/JCO.2008.20.2853.
94. Hong A, Jones D, Chatfield M, Soon Lee C, Zhang M, Clark J, et al. HPV Status of Oropharyngeal Cancer by Combination HPV-DNA/p16 Testing: Biological Relevance of Discordant Results. Ann Surg Oncol 2012 (Epub 04 December 2012).
95. Villa LL. HPV prophylactic vaccination: The first years and what to expect from now. Cancer Lett 2011; 305: 106-112, doi: 10.1016/j.canlet.2010.12.002.